Palatin Technologies (PTN) Misses Q4 EPS by 3c; Updates on Cash Postion

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/2/2026

1. CRWD
2. REGN
3. ABBV
4. CL
5. TFII
6. LYB
7. LITE
8. NVT
9. SPY
10. AAPL

Go back to Palatin Technologies (PTN) Misses Q4 EPS by 3c; Updates on Cash Postion

Palatin Technologies, Inc. Reports Fourth Quarter And Fiscal Year 2016 Results

September 20, 2016 7:30 AM EDT

CRANBURY, N.J., Sept. 20, 2016 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced financial results for its fourth quarter and fiscal year ended June 30, 2016. 

Significant Highlights

Bremelanotide - Under development for Hypoactive Sexual Desire Disorder (HSDD): Palatin's two Phase 3 clinical trials for the treatment of HSDD randomized a total of approximately 1,250 women to evaluate efficacy and safety of subcutaneous... More